Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 5, 2007, Pages 1206-1212

  Stoll, Patrick ^a,b   Bassler, Nicole ^a   Hagemeyer, Christoph E ^a   Eisenhardt, Steffen U ^a   Chen, Yung Chih ^a   Schmidt, Rene ^b   Schwarz, Meike ^b   Ahrens, Ingo ^b   Katagiri, Yasuhiro ^c   Pannen, Benedikt ^d   Bode, Christoph ^b   Peter, Karlheinz ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF FREIBURG   (Germany)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Anticoagulation; fXa; GPIIb IIIa; Single chain; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; ENOXAPARIN; FERRIC CHLORIDE; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN G LIGAND INDUCED BINDING SITE ANTIBODY BINDING PROTEIN; LIGAND; RECOMBINANT TICK ANTICOAGULANT PEPTIDE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY LIGAND INDUCED BINDING SITE ANTIBODY FUSION PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY LIGAND INDUCED BINDING SITE ANTIBODY TICK ANTICOAGULANT PEPTIDE FUSION PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY TICK ANTICOAGULANT PEPTIDE FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BINDING SITE; BIOASSAY; BLEEDING; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DISEASE MODEL; DOPPLER FLOWMETER; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG TARGETING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES, ANTIBODY; BLOOD PLATELETS; BLOTTING, WESTERN; EPITOPES; FLOW CYTOMETRY; GENE EXPRESSION; HEMORRHAGE; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOLOGIC FACTORS; LIGANDS; MICE; MICE, INBRED C57BL; PLATELET AGGREGATION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN BINDING; RISK FACTORS; THROMBOSIS;

EID: 34247402058     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.106.138875     Document Type: Article

References (42)

1. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:287S-310S.
2. Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost. 2005;3:1843-1853.
3. Spyropoulos AC. Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients. Chest. 2005;128:958-969.
4. Hagemeyer CE, Tomic I, Jaminet P, Weirich U, Bassler N, Schwarz M, Runge MS, Bode C, Peter K. Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide. Thromb Haemost. 2004;92:47-53.
5. Peter K, Graeber J, Kipriyanov S, Zewe-Welschof M, Runge MS, Kubler W, Little M, Bode C. Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa. Circulation. 2000;101:1158-1164.
6. Peter K, Gupta A, Nordt T, Bauer S, Runge MS, Bode C. Construction and in vitro testing of a novel fab-hirudin-based fusion protein that targets fibrin and inhibits thrombin in a factor xa-dependent manner. J Cardiovasc Pharmacol. 2003;42:237-244.
7. Bode C, Hanson SR, Schmedtje JF Jr, Haber E, Mehwald P, Kelly AB, Harker LA, Runge MS. Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting. Circulation. 1997;95:800-804.
8. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol. 2003;23:17-25.
9. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2:15-28.
10. Gawaz M, Neumann FJ, Schomig A. Evaluation of platelet membrane glycoproteins in coronary artery disease : consequences for diagnosis and therapy. Circulation. 1999;99:E1-E11.
11. Schwarz M, Katagiri Y, Kotani M, Bassler N, Loeffler C, Bode C, Peter K. Reversibility versus persistence of GPIIb/IIIa blocker-induced conformational change of GPIIb/IIIa (alphaIIbbeta3, CD41/CD61). J Pharmacol Exp Ther. 2004;308:1002-1011.
12. Breitling F, Duebel, S. Recombinant Antibodies. New York: John Wiley & Sons; 1999.
13. Smith KA, Nelson PN, Warren P, Astley SJ, Murray PG, Greenman J. Demystified . . . recombinant antibodies. J Clin Pathol. 2004;57:912-917.
14. Hagemeyer CE, Tomic I, Weirich U, Graeber J, Nordt T, Runge MS, Bode C, Peter K. Construction and characterization of a recombinant plasminogen activator composed of an anti-fibrin single-chain antibody and low-molecular-weight urokinase. J Thromb Haemost. 2004;2:797-803.
15. Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science. 1990;248:593-596.
16. Schaffer LW, Davidson JT, Vlasuk GP, Siegl PK. Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation. 1991;84:1741-1748.
17. Wang X, Xu L. An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. Thromb Res. 2005;115:95-100.
18. Jirouskova M, Chereshnev I, Vaananen H, Degen JL, Coller BS. Antibody blockade or mutation of the fibrinogen gamma-chain C-terminus is more effective in inhibiting murine arterial thrombus formation than complete absence of fibrinogen. Blood. 2004;103:1995-2002.
19. Schafer K, Konstantinides S, Riedel C, Thinnes T, Muller K, Dellas C, Hasenfuss G, Loskutoff DJ. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase- or tissue-type plasminogen activator. Circulation. 2002;106:1847-1852.
20. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002;22:1381-1389.
21. Fateh-Moghadam S, Bocksch W, Ruf A, Dickfeld T, Schartl M, Pogatsa-Murray G, Hetzer R, Fleck E, Gawaz M. Changes in surface expression of platelet membrane glycoproteins and progression of heart transplant vasculopathy. Circulation. 2000;102:890-897.
22. Coller BS. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost. 2001;86:427-443.
23. Holvoet P, Laroche Y, Stassen JM, Lijnen HR, Van Hoef B, De Cock F, Van Houtven A, Gansemans Y, Matthyssens G, Collen D. Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase. Blood. 1993;81:696-703.
24. Imura Y, Stassen JM, Kurokawa T, Iwasa S, Lijnen HR, Collen D. Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. Blood. 1992;79:2322-2329.
25. Runge MS, Harker LA, Bode C, Ruef J, Kelly AB, Marzec UM, Allen E, Caban R, Shaw SY, Haber E, Hanson SR. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation. 1996;94:1412-1422.
26. Chen HH, Vicente CP, He L, Tollefsen DM, Wun TC. Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants. Blood. 2005;105:3902-3909.
27. Dong N, Da Cunha V, Citkowicz A, Wu F, Vincelette J, Larsen B, Wang YX, Ruan C, Dole WP, Morser J, Wu Q, Pan J. P-selectin-targeting of the fibrin selective thrombolytic Desmodus rotundus salivary plasminogen activator alpha1. Thromb Haemost. 2004;92:956-965.
28. Murciano JC, Medinilla S, Eslin D, Atochina E, Cines DB, Muzykantov VR. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol. 2003;21:891-896.
29. Ding BS, Gottstein C, Grunow A, Kuo A, Ganguly K, Albelda SM, Cines DB, Muzykantov VR. Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood. 2005;106:4191-4198.
30. Kufrin D, Eslin DE, Bdeir K, Murciano JC, Kuo A, Kowalska MA, Degen JL, Sachais BS, Cines DB, Poncz M. Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood. 2003;102:926-933.
31. McKenzie CR, Abendschein DR, Eisenberg PR. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler Thromb Vasc Biol. 1996;16:1285-1291.
32. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
33. Abendschein DR, Baum PK, Verhallen P, Eisenberg PR, Sullivan ME, Light DR. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs. J Pharmacol Exp Ther. 2001;296:567-572.
34. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation. 1992;85:805-815.
35. Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the procoagulant activity of whole-blood clots. J Clin Invest. 1993;91:1877-1883.
36. Feldhaus MJ, Siegel RW. Yeast display of antibody fragments: a discovery and characterization platform. J Immunol Methods. 2004;290:69-80.
37. Schwarz M, Rottgen P, Takada Y, Le Gall F, Knackmuss S, Bassler N, Buttner C, Little M, Bode C, Peter K. Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries. Faseb J. 2004;18:1704-1706.
38. Eisenhardt SU, Schwarz M, Schallner N, Soosairajah J, Bassler N, Huang D, Bode C, Peter K. Generation of activation-specific human anti-{alpha}M{beta}2 single-chain antibodies as potential diagnostic tools and therapeutic agents. Blood. In press.
39. Graff CP, Chester K, Begent R, Wittrup KD. Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Eng Des Sel. 2004;17:293-304.
40. Huhalov A, Chester KA. Engineered single chain antibody fragments for radioimmunotherapy. Q J Nucl Med Mol Imaging. 2004;48:279-288.
41. Sharma SK, Pedley RB, Bhatia J, Boxer GM, El-Emir E, Qureshi U, Tolner B, Lowe H, Michael NP, Minton N, Begent RH, Chester KA. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Clin Cancer Res. 2005;11:814-825.
42. Leath CA, 3rd, Douglas JT, Curiel DT, Alvarez RD. Single-chain antibodies: A therapeutic modality for cancer gene therapy (review). Int J Oncol. 2004;24:765-771.